ReproNovo Phase 2 fertility study doses first participant
pharmafile | July 10, 2026 | News story | Research and Development | ReproNovo, fertility study
ReproNovo has dosed the first participant in its phase 2 NORDIC study evaluating RPN-002, an investigational therapy designed to improve embryo implantation during assisted reproductive technology (ART).
The randomised, double-blind, placebo-controlled trial will enrol 120 participants across five European sites and will investigate whether higher doses and longer treatment schedules can reduce uterine contractions around embryo transfer.
Successful embryo implantation remains one of the greatest challenges in in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), with many couples undergoing repeated treatment cycles before achieving pregnancy.
Joan-Carles Arce, Chief Scientific and Medical Officer of ReproNovo, said: “NORDIC is designed to generate the pharmacodynamic evidence needed to guide selection of an optimized dosing regimen for future clinical evaluation in improving implantation rates in IVF and ICSI.”
The study will assess uterine contractility together with endocrine parameters that may influence embryo implantation.
Juan García Velasco, Chief Scientific Officer of IVIRMA, representing the study investigators, said implantation remained “one of the most critical and uncertain steps” in assisted reproduction and that the findings could help guide future fertility treatments.
RPN-002 is an oral oxytocin receptor antagonist designed to reduce uterine contractility and maintain uterine quiescence during embryo transfer.
ReproNovo said the study forms part of a wider clinical programme investigating treatments for male and female infertility and women’s health conditions.
